UY29185A1 - SOLID ORAL DOSAGE FORMS CONTAINING A LOW ESTRADIOL DOSE - Google Patents

SOLID ORAL DOSAGE FORMS CONTAINING A LOW ESTRADIOL DOSE

Info

Publication number
UY29185A1
UY29185A1 UY29185A UY29185A UY29185A1 UY 29185 A1 UY29185 A1 UY 29185A1 UY 29185 A UY29185 A UY 29185A UY 29185 A UY29185 A UY 29185A UY 29185 A1 UY29185 A1 UY 29185A1
Authority
UY
Uruguay
Prior art keywords
dosage forms
solid oral
estrodiol
oral dosage
forms containing
Prior art date
Application number
UY29185A
Other languages
Spanish (es)
Inventor
Kristina Muller
Torsten Wagner
Adrian Funke
Christian Zurth
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of UY29185A1 publication Critical patent/UY29185A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Formas de dosificación oral sólida que contienen una dosis muy baja de estrodiol. Las formas de dosificación se formulan de modo tal que se evita la degradación del estrodiol y se minimiza el contenido de polivinilpirrolidona, al tiempo que aaún se logra una disolución rápida similar del estrodiol. Las formas de dosificación son útiles para prevenir o tratar una condición física en una mujer, provocada por niveles endógenos insuficientes de estrodiol.Solid oral dosage forms that contain a very low dose of estrodiol. The dosage forms are formulated in such a way that degradation of estrodiol is avoided and the polyvinylpyrrolidone content is minimized, while still achieving a similar rapid dissolution of estrodiol. Dosage forms are useful for preventing or treating a physical condition in a woman, caused by insufficient endogenous levels of estrodiol.

UY29185A 2004-11-02 2005-10-31 SOLID ORAL DOSAGE FORMS CONTAINING A LOW ESTRADIOL DOSE UY29185A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04078014 2004-11-02

Publications (1)

Publication Number Publication Date
UY29185A1 true UY29185A1 (en) 2006-05-31

Family

ID=34928627

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29185A UY29185A1 (en) 2004-11-02 2005-10-31 SOLID ORAL DOSAGE FORMS CONTAINING A LOW ESTRADIOL DOSE

Country Status (21)

Country Link
EP (1) EP1814526A2 (en)
JP (1) JP2008518895A (en)
KR (1) KR20070085558A (en)
CN (1) CN101094656A (en)
AR (1) AR053650A1 (en)
AU (1) AU2005300658A1 (en)
BR (1) BRPI0517940A (en)
CA (1) CA2585095A1 (en)
CR (1) CR9112A (en)
CU (1) CU20070094A7 (en)
EA (1) EA013262B1 (en)
GT (1) GT200500315A (en)
IL (1) IL182635A0 (en)
MX (1) MX2007005281A (en)
NO (1) NO20072704L (en)
PA (1) PA8651401A1 (en)
PE (1) PE20061126A1 (en)
TW (1) TW200621312A (en)
UY (1) UY29185A1 (en)
WO (1) WO2006048261A2 (en)
ZA (1) ZA200705012B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022053B2 (en) 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
KR20080047956A (en) * 2006-11-27 2008-05-30 주식회사 엠디바이오알파 Pharmaceutical composition for treatment and prevention of diseases involving impotence
DE102009007771B4 (en) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Buccal administration system containing 17α-estradiol
CA2795801C (en) * 2010-04-15 2018-05-29 Bayer Intellectual Property Gmbh Very low-dosed solid oral dosage forms for hrt
ES2533584T3 (en) 2010-04-15 2015-04-13 Bayer Intellectual Property Gmbh Solid low dose oral dosage forms for TSH
CN112516149B (en) * 2020-07-21 2023-07-18 南方医科大学 Application of estradiol benzoate or pharmaceutically acceptable salt thereof in preparation of anti-coronavirus drugs

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL125069C (en) * 1963-12-24
US4755386A (en) * 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
FR2739558B1 (en) * 1995-10-05 1997-11-28 Innothera Lab Sa UNITAL GALENIC FORM FOR LOCAL HORMONOTHERAPY OF VAGINAL DROUGHT
FR2754179B1 (en) * 1996-10-08 1998-12-24 Theramex NOVEL HORMONONAL COMPOSITION AND ITS USE
US6326366B1 (en) * 2000-08-22 2001-12-04 Protein Technologies International Hormone replacement therapy
US7498303B2 (en) * 2000-10-30 2009-03-03 University Of Zuerich GNRH analogues for treatment of urinary incontinence
WO2002047692A1 (en) * 2000-12-15 2002-06-20 Novo Nordisk A/S Use of an oestrogen in the manufacture of a composition containing oestrogen for the treatment of atrophic vaginitis
FR2823976A1 (en) * 2001-04-25 2002-10-31 Theramex NOVEL HORMONAL COMPOSITION AND ITS USE
US20030018018A1 (en) * 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
US6962908B2 (en) * 2001-12-21 2005-11-08 Warner Chilcott Company Inc. Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
JP2004155779A (en) * 2002-10-16 2004-06-03 Taisho Pharmaceut Co Ltd Peroral composition for preventing and treating climacteric symptom

Also Published As

Publication number Publication date
EP1814526A2 (en) 2007-08-08
EA013262B1 (en) 2010-04-30
KR20070085558A (en) 2007-08-27
CA2585095A1 (en) 2006-05-11
CN101094656A (en) 2007-12-26
PA8651401A1 (en) 2006-12-07
ZA200705012B (en) 2008-10-29
WO2006048261A2 (en) 2006-05-11
AR053650A1 (en) 2007-05-16
GT200500315A (en) 2006-06-06
JP2008518895A (en) 2008-06-05
EA200700979A1 (en) 2007-10-26
CU20070094A7 (en) 2009-09-08
BRPI0517940A (en) 2008-10-21
NO20072704L (en) 2007-05-29
CR9112A (en) 2007-11-23
TW200621312A (en) 2006-07-01
IL182635A0 (en) 2007-07-24
MX2007005281A (en) 2008-03-11
PE20061126A1 (en) 2006-11-11
WO2006048261A3 (en) 2006-09-21
AU2005300658A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
ES2557988T3 (en) Method to treat prostate diseases based on the local supply of active ingredients
AR109263A2 (en) COMPOSITION INCLUDING MOXIDECTINE
AR077573A2 (en) USE OF A TNF INHIBITOR AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
UY29185A1 (en) SOLID ORAL DOSAGE FORMS CONTAINING A LOW ESTRADIOL DOSE
AR068185A1 (en) COMPOSITIONS OF LAMOTRIGIN ORAL DISINTEGRATION TABLETS
AR046510A1 (en) COMPOSITION OF A VEGF ANTAGONIST AND AN ANTI-PROLIFERATIVE AGENT
ECSP066553A (en) MASTICABLE ADMINISTRATION FORMS, NOT INDIVIDUALLY DOSED COMPRESSED.
EE200400020A (en) Substituted oxazolidinones for combination therapy
AR055095A1 (en) NEW MACROCICLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
ECSP066378A (en) "AN ISOXAZOLINE DERIVATIVE AS AN INHIBITOR AGAINST VARIOUS CASPASES, A PROCEDURE TO PREPARE THE SAME AND A THERAPEUTIC COMPOSITION TO PREVENT INFLAMMATION AND THE APOTOSIS THAT UNDERSTANDS HIMSELF"
ECSP066805A (en) SILINAN COMPOUNDS AS INHIBITORS OF CYSTEINE PROTEASA
CU23821A3 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A DIFFENILUREA REPLACED WITH OMEGA-CARBOXIARIL FOR THE TREATMENT OF CANCER
PE20070333A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING AGOMELATIN FOR THE TREATMENT OF SLEEP DISORDERS IN DEPRESSED PATIENTS
UY29274A1 (en) PHARMACEUTICAL COMPOSITION TO TREAT HYPERTENSION, WHICH INCLUDES TELMISARTANE AND HYDROCLOROTIAZIDA
ATE476997T1 (en) COMPOSITION AND DOSAGE FORM COMPRISING A SOLID OR SEMI-SOLID MATRIX
BRPI0411324A (en) pharmaceutical compositions and methods of treating histamine-mediated response in patients
UY28154A1 (en) ORAL CARE COMPOSITIONS AND METHODS
AR058298A1 (en) VETERINARY COMPOSITION
AR039977A1 (en) DICLOFENAC BASED COMPOSITION FOR THE TOPICAL TREATMENT OF OROPHARINGEA CAVITY AFFECTIONS
AR043013A1 (en) PHARMACEUTICAL COMPOSITION INTENDED FOR THE TREATMENT OF ENDOMETRIOSIS
AR048355A1 (en) ASSOCIATION BETWEEN A HETEROCICLICAL COMPOUND AND AN ANTIOXIDANT AGENT AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ES2504365T3 (en) The neuroprotective activity of activated protein C is independent of its anticoagulant activity
AR029718A1 (en) PHARMACEUTICAL COMPOSITION BASED ON COCAETHYLENE AND ITS USE FOR THE TREATMENT OF THE DEPENDENCY OF PSYCHOACTIVE SUBSTANCES
AR037981A1 (en) USE OF MELOXICAM IN COMBINATION WITH AN ANTIPLAQUETARY AGENT FOR THE TREATMENT OF THE ACUTE CORONARY SYNDROME AND RELATED CONDITIONS
AR057161A1 (en) METHODS AND DOSAGE FORMS OF BENZISOXAZOL DERIVATIVES WITH BETTER EFFECTIVENESS

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160525